Precision Medicine for Rheumatoid Arthritis: The Right Drug for the Right Patient-Companion Diagnostics

Overview

Journal Diagnostics (Basel)

Specialty Radiology

Date 2021 Aug 27

PMID 34441297

Citations 7

Authors

Richard Thomas Meehan

Isabelle Anne Amigues

Vijaya Knight

Affiliations

Soon will be listed here.

Abstract

Despite the growing number of biologic and JAK inhibitor therapeutic agents available to treat various systemic autoimmune illnesses, the lack of a validated companion diagnostic (CDx) to accurately predict drug responsiveness for an individual results in many patients being treated for years with expensive, ineffective, or toxic drugs. This review will focus primarily on rheumatoid arthritis (RA) therapeutics where the need is greatest due to poor patient outcomes if the optimum drug is delayed. We will review current FDA-approved biologic and small molecule drugs and why RA patients switch these medications. We will discuss the sampling of various tissues for potential CDx and review early results from studies investigating drug responsiveness utilizing advanced technologies including; multiplex testing of cytokines and proteins, autoantibody profiling, genomic analysis, proteomics, miRNA analysis, and metabolomics. By using these new technologies for CDx the goal is to improve RA patient outcomes and achieve similar successes like those seen in oncology using precision medicine guided therapeutics.

Citing Articles

Multistage deep learning methods for automating radiographic sharp score prediction in rheumatoid arthritis.

Moradmand H, Ren L Sci Rep. 2025; 15(1):3391.

PMID: 39870749 PMC: 11772782. DOI: 10.1038/s41598-025-86073-0.

Computational discovery of AKT serine/threonine kinase 1 inhibitors through shape screening for rheumatoid arthritis intervention.

Rangaswamy R, Sneha S, Hemavathy N, Umashankar V, Jeyakanthan J Mol Divers. 2024; 29(2):1287-1303.

PMID: 38970640 DOI: 10.1007/s11030-024-10910-z.

PTEN: an emerging target in rheumatoid arthritis?.

Zhou P, Meng X, Nie Z, Wang H, Wang K, Du A Cell Commun Signal. 2024; 22(1):246.

PMID: 38671436 PMC: 11046879. DOI: 10.1186/s12964-024-01618-6.

Non-trough adalimumab and certolizumab drug levels associated with a therapeutic EULAR response in adherent patients with rheumatoid arthritis.

Hum R, Ho P, Nair N, Jani M, Morgan A, Isaacs J Rheumatology (Oxford). 2022; 62(6):2090-2097.

PMID: 36190343 PMC: 10234202. DOI: 10.1093/rheumatology/keac564.

Effectiveness and Safety of Iguratimod Monotherapy or Combined With Methotrexate in Treating Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.

Ouyang D, Ma Y, Zou J, Wang Y, Chen Z, Yang Y Front Pharmacol. 2022; 13:911810.

PMID: 35991879 PMC: 9389904. DOI: 10.3389/fphar.2022.911810.

References

Potter C, Hyrich K, Tracey A, Lunt M, Plant D, Symmons D . Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis. Ann Rheum Dis. 2008; 68(1):69-74. PMC: 2596303. DOI: 10.1136/ard.2007.084715. View

Scher J, Abramson S . The microbiome and rheumatoid arthritis. Nat Rev Rheumatol. 2011; 7(10):569-78. PMC: 3275101. DOI: 10.1038/nrrheum.2011.121. View

Cuppen B, Fu J, van Wietmarschen H, Harms A, Koval S, Marijnissen A . Exploring the Inflammatory Metabolomic Profile to Predict Response to TNF-α Inhibitors in Rheumatoid Arthritis. PLoS One. 2016; 11(9):e0163087. PMC: 5025050. DOI: 10.1371/journal.pone.0163087. View

Benucci M, Li Gobbi F, Meacci F, Manfredi M, Infantino M, Severino M . Antidrug antibodies against TNF-blocking agents: correlations between disease activity, hypersensitivity reactions, and different classes of immunoglobulins. Biologics. 2015; 9:7-12. PMC: 4337417. DOI: 10.2147/BTT.S69606. View

Dadoun S, Zeboulon-Ktorza N, Combescure C, Elhai M, Rozenberg S, Gossec L . Mortality in rheumatoid arthritis over the last fifty years: systematic review and meta-analysis. Joint Bone Spine. 2012; 80(1):29-33. DOI: 10.1016/j.jbspin.2012.02.005. View

Maricar N, Parkes M, Callaghan M, Felson D, ONeill T . Where and how to inject the knee--a systematic review. Semin Arthritis Rheum. 2013; 43(2):195-203. PMC: 3820023. DOI: 10.1016/j.semarthrit.2013.04.010. View

Bhattacharjee M, Balakrishnan L, Renuse S, Advani J, Goel R, Sathe G . Synovial fluid proteome in rheumatoid arthritis. Clin Proteomics. 2016; 13:12. PMC: 4893419. DOI: 10.1186/s12014-016-9113-1. View

Osiri M, Wongpiyabovorn J, Sattayasomboon Y, Thammacharoenrach N . Inflammatory cytokine levels, disease activity, and function of patients with rheumatoid arthritis treated with combined conventional disease-modifying antirheumatic drugs or biologics. Clin Rheumatol. 2016; 35(7):1673-81. DOI: 10.1007/s10067-016-3306-x. View

Mini E, Nobili S . Pharmacogenetics: implementing personalized medicine. Clin Cases Miner Bone Metab. 2012; 6(1):17-24. PMC: 2781211. View

10.

Sibbitt Jr W, Peisajovich A, Michael A, Park K, Sibbitt R, Band P . Does sonographic needle guidance affect the clinical outcome of intraarticular injections?. J Rheumatol. 2009; 36(9):1892-902. DOI: 10.3899/jrheum.090013. View

11.

Liao H, Wu J, Kuhn E, Chin W, Chang B, Jones M . Use of mass spectrometry to identify protein biomarkers of disease severity in the synovial fluid and serum of patients with rheumatoid arthritis. Arthritis Rheum. 2004; 50(12):3792-803. DOI: 10.1002/art.20720. View

12.

Zhang F, Wei K, Slowikowski K, Fonseka C, Rao D, Kelly S . Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometry. Nat Immunol. 2019; 20(7):928-942. PMC: 6602051. DOI: 10.1038/s41590-019-0378-1. View

13.

Folkersen L, Brynedal B, Diaz-Gallo L, Ramskold D, Shchetynsky K, Westerlind H . Integration of known DNA, RNA and protein biomarkers provides prediction of anti-TNF response in rheumatoid arthritis: results from the COMBINE study. Mol Med. 2016; 22:322-328. PMC: 5023516. DOI: 10.2119/molmed.2016.00078. View

14.

Davis 3rd J . Editorial: The Multi-Biomarker Disease Activity Test for Rheumatoid Arthritis: Is It a Valid Measure of Disease Activity?. Arthritis Rheumatol. 2016; 68(9):2061-6. DOI: 10.1002/art.39716. View

15.

Bodenmiller B, Zunder E, Finck R, Chen T, Savig E, Bruggner R . Multiplexed mass cytometry profiling of cellular states perturbed by small-molecule regulators. Nat Biotechnol. 2012; 30(9):858-67. PMC: 3627543. DOI: 10.1038/nbt.2317. View

16.

Gupta L, Ahmed S, Jain A, Misra R . Emerging role of metabolomics in rheumatology. Int J Rheum Dis. 2018; 21(8):1468-1477. DOI: 10.1111/1756-185X.13353. View

17.

Blaschke S, Rinke K, Maring M, Flad T, Patschan S, Jahn O . Haptoglobin-α1, -α2, vitamin D-binding protein and apolipoprotein C-III as predictors of etanercept drug response in rheumatoid arthritis. Arthritis Res Ther. 2015; 17:45. PMC: 4383078. DOI: 10.1186/s13075-015-0553-1. View

18.

Meehan R, Wilson C, Hoffman E, Altimier L, Kaessner M, Regan E . Ultrasound measurement of knee synovial fluid during external pneumatic compression. J Orthop Res. 2019; 37(3):601-608. DOI: 10.1002/jor.24216. View

19.

Juarez M, Bang H, Hammar F, Reimer U, Dyke B, Sahbudin I . Identification of novel antiacetylated vimentin antibodies in patients with early inflammatory arthritis. Ann Rheum Dis. 2015; 75(6):1099-107. PMC: 4893102. DOI: 10.1136/annrheumdis-2014-206785. View

20.

Dwivedi R, Dhindsa N, Krokhin O, Cortens J, Wilkins J, El-Gabalawy H . The effects of infliximab therapy on the serum proteome of rheumatoid arthritis patients. Arthritis Res Ther. 2009; 11(2):R32. PMC: 2688177. DOI: 10.1186/ar2637. View